Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11170775 | 0.81 | P2RX4 (0.41) | ALDH1A1MEN1KMT2AP2RX4KDM4E | |
| SCHEMBL30753563 | 0.71 | KMT2A (0.42) | SLC6A4DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL9008261 | 0.71 | KMT2A (0.42) | SLC6A4DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL12776605 | 0.70 | P2RX4 (0.49) | ALDH1A1MEN1KMT2AP2RX4KDM4E | |
| SCHEMBL31587978 | 0.70 | P2RX4 (0.38) | ALDH1A1P2RX4MAPT | |
| SCHEMBL15413770 | 0.70 | P2RX4 (0.40) | ALDH1A1P2RX4KDM4EGLAGAA | |
| SCHEMBL16736488 | 0.66 | P2RX4 (0.43) | ALDH1A1MEN1KMT2AP2RX4KDM4E | |
| Ammonia Solution, Strong SCHEMBL4822367 | 0.66 | ALDH1A1 (0.41) | SLC6A4DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL275515 | 0.65 | MAPT (0.37) | SLC6A4DRD2ALDH1A1MEN1KMT2A | |
| SCHEMBL26555682 | 0.64 | P2RX4 (0.43) | ALDH1A1MEN1KMT2AP2RX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | SLC6A4 289/4885DRD2 9/4885ALDH1A1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.